Bluebird Bio Faces Pandemic Disruption Derivative Suit (1)

Bluebird bio Inc.'s leadership allegedly misled shareholders about the license application for its sickle cell drug and the “forseeable impact” of coronavirus-related disruptions, a derivative suit filed in federal court in Delaware says.

The biotechnology company’s directors and officers didn’t tell investors that its licensing push for LentiGlobin for sickle cell disease currently lacked sufficient data to “demonstrate drug product comparability,” according to the shareholder derivative complaint filed in the U.S. District Court for the District of Delaware.

Bluebird also failed to tell investors how it had “downplayed” how pandemic disruptions would affect its submission schedule for the drug, “particularly ...